Multi-matrix system mesalamine: To use or not to use

Annals of Pharmacotherapy

Volumn 42, Issue 2, 2008, Pages 265-269

  Kale Pradhan, Pramodini B ^a,b   Pradhan, Rohan S ^a   Wilhelm, Sheila M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Lialda; Mesalamine; MMX; SDP476; Ulcerative colitis

Indexed keywords

MESALAZINE;

ABDOMINAL PAIN; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TOLERABILITY; DRUG USE; FLATULENCE; HEADACHE; HUMAN; LONG TERM CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; REVIEW; ULCERATIVE COLITIS;

CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; DRUG DELIVERY SYSTEMS; HUMANS; MESALAMINE;

EID: 39049107664     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K469     Document Type: Review

References (18)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85.
2. Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am 2007;87:575-85.
3. Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;24:465-74.
4. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(suppl 5):V1-16.
5. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48:571-7.
6. Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am 2004;33:303-17, ix-x.
7. Tamboli CP. Current medical therapy for chronic inflammatory bowel diseases. Surg Clin North Am 2007;87:697-725.
8. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-85.
9. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114:39-43.
10. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98: 1535-44.
11. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:191-8.
12. Baker DE. MMX mesalamine. Rev Gastroenterol Disord 2006;6:146-52.
13. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11:421-7.
14. D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006;24:1087-97.
15. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102.
16. Kamm MA, Sandbom WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75; quiz 432-3.
17. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
18. Fleming T, ed. Red book: pharmacy's fundamental reference (red book drug topics). Montvale, NJ: Thompson, 2007.